

Notification:	HUM 7651
<u>Category:</u>	HCPCS - Drugs & Biologicals
Topic:	Louisiana Medicaid: HCPCS codes J1745, Q5103, Q5104, Q5109 and
	Q5121 – infliximab and its biosimilars
What is changing? /	For providers with a specialty other than home infusion therapy or
Change Description:	pharmacy, we limit reimbursement of charges for HCPCS codes J1745,
	Q5103, Q5104, Q5109 or Q5121 to no more than 49 units per date of
	service for patients ages 6–8 with a diagnosis of ulcerative colitis
	(pediatric).
Why is Humana making this change?	The limitations above are established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	compendia.
	Note: The limitations described above are based on maximum
	dosages established in milligrams. If any units are denied, the
	provider may dispute the decision through the appropriate process.
	The provider may submit information, including medical notes
	showing the patient's body weight, that substantiates the medical
	necessity of the additional units.
<u>Language:</u>	<u>English</u>
Impacted Products:	Medicaid- Louisiana